Going forward..., page-499

Twitter seems to be becoming Cynata's preferred news channel:

https://twitter.com/cynatastemcells/status/1087107609461702657

On 03/01/19 it was:
"Our manufacturing partner, FUJIFILM Cellular Dynamics will be building a new USD21m facility in the US for the production of its induced pluripotent stem cells - the starting material for our Cymerus platform."

Now it is:
"Fujifilm has established a new facility for the production of iPS cell therapy applications. Through partnering with CYP, Fujifilm will be able to leverage CYP CymerusTM technology for large scale production of cell therapy products derived from iPS cells."

Differences are:

- FUJIFILM - not only its subsidiary CDI

- large scale production of cell therapy products - PLURAL, not only CYP-001 in GvHD, which is ONE product




We already know from the same asx announcement that FUJIFILM has the option to also manufacture CYP-001 in GvHD - which will atract further fees. How about multiple products then?
CYP-001 is the title of one specific product, given that our CLI product will be called CYP-002.

- leverage CYP CymerusTM technology for large scale production of cell therapy products derived from iPS cells - not only production of its induced pluripotent stem cells - the starting material for our Cymerus platform, this is the platform itself!

Two Tweets, talking about the same manufacturing facility, yet telling us completely different things. While the first Tweet was telling us that FUJIFILM CDI is the manufacturing partner for our iPS starting material, it is now FUJIFILM that will be leveraging our technology for large-scale manufacturing of more than one iPS product.

What products? The $ amounts attached to these various manufacturing options? I guess we have to wait - and keep reading Cynata's Twitter account